New England Journal of Medicine publishes positive final results from phase 1/2a study of BIVV001 in people with severe haemophilia A
· BIVV001 is the first investigational factor VIII therapy independent of von Willebrand factor and has the potential to transform replacement therapy for people with haemophilia A · It is uniquely designed to deliver near-normal factor activity levels for the majority of the week, extending bleed protection in a once-weekly dose · Results from the phase 1/2a study showed that a single dose of BIVV001 achieved high sustained factor activity and a three- to four-fold increase in half-life when compared to conventional factor VIII replacement therapies Stockholm & Paris – The New